Trial Profile
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Filgotinib (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms DIVERGENCE 1
- Sponsors Gilead Sciences
- 06 Aug 2020 Status changed from active, no longer recruiting to completed.
- 24 Feb 2020 Status changed from recruiting to active, no longer recruiting.
- 28 May 2019 Planned End Date changed from 1 Mar 2020 to 1 Jul 2020.